BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 20, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Actonel risedronate: Post-marketing study data

A task force of the American Society for Bone and Mineral Research reported a review of both published and unpublished data suggesting that the risk of atypical femoral fractures increases with the duration of exposure to bisphosphonates for osteoporosis. Specifically, a review of 310 cases of atypical femur fractures showed that 94% of patients had taken bisphosphonates for >5 years. The report also noted that more than half of patients with...

Read the full 331 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >